Seneca Therapeutics
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
202 Saint Andrews Ct, Blue Bell, Pennsyl...Website
www.senecatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Seneca Therapeutics
Seneca Therapeutics, Inc. (Seneca) is developing a pipeline of novel cancer agents using the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001). The first product anticipated to be in later stage clinical trials in 2021 is SVV-001 itself. SVV-001 is targeted immunotherapy that selectively kills cancer cells expressing the SVV-001's receptor, TEM-8, and stimulates the immune system to attack the tumor. SVV-001 is demonstrated to synergize with immune checkpoint inhibitors and other cancer agents to significantly benefit more cancer patients.Explore more
Seneca Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seneca Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Seneca Therapeutics is spiking on competitors!
Earning: See what the market has to say on Seneca Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Seneca Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Seneca Therapeutics launches new products
Seneca Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Seneca Therapeutics has new funding data
Click to see if Seneca Therapeutics had a recent Job posting/layoffs
Check if Seneca Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Seneca Therapeutics
Compare insights from companies similar to Seneca Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Seneca Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Seneca Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Seneca Therapeutics.
Seneca Therapeutics financials insights
Gather financial insights about Seneca Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$5M
Seneca Therapeutics Tech Stack
A closer look at the technologies used by Seneca Therapeutics
Most Recent Scoops
Executive Move
Board of Directors
Funding
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Seneca Therapeutics
Sign Up For FreeTo access detailed company insights
Seneca Therapeutics, Inc. (Seneca) is developing a pipeline of novel cancer agents using the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001). The first product anticipated to be in later stage clinical trials in 2021 is SVV-001 itself. SVV-001 is targeted immunotherapy that selectively kills cancer cells expressing the SVV-001's receptor, T... Read More
